LONDON, July 27 (Reuters) - GlaxoSmithKline plans275 million pounds ($361 million) of new investments at threedrug manufacturing sites in Britain, signalling its confidencein the country despite last month's vote to leave the EuropeanUnion. (Reporting by Ben Hirschler; Editing by David Holmes)
Glaxosmithkline (GSK)Today 19:57
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a...
